Monopar Therapeutics, EDNOC announce EAP for MNPR-101-Zr, MNPR-101-Lu

Monopar Therapeutics (MNPR) in collaboration with Excel Diagnostics and Nuclear Oncology Center, EDNOC, a premier diagnostic medical imaging and therapeutic nuclear medicine center, announced that the physician-sponsored Expanded Access Program, EAP, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu has received authorization to proceed from the U.S. Food and Drug Administration. “We are pleased to provide patients in the United States with access to MNPR-101-Zr and MNPR-101-Lu, which were developed to target aggressive cancers, such as triple-negative breast, pancreatic, and colorectal cancer,” said Andrew Cittadine, Chief Operating Officer of Monopar. “This EAP represents continued progress in our radiopharmaceutical pipeline following last year’s initiation of Phase 1 clinical trials in Australia with MNPR-101-Zr and MNPR-101-Lu. We are grateful for the opportunity to work with Dr. Delpassand to make these therapies available to patients on a compassionate use basis,” added Cittadine.